Search Results (160)
Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Drug-drug interactions during antiviral therapy for chronic hepatitis C. | Academic Article |
Why?
|
| Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B. | Academic Article |
Why?
|
| Acute loss of vision in a patient with chronic hepatitis C. | Academic Article |
Why?
|
| Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C. | Academic Article |
Why?
|
| Ledipasvir-Sofosbuvir for 12?Weeks in Children 3 to <6?Years Old With Chronic Hepatitis C. | Academic Article |
Why?
|
| Management of the transplant recipient with chronic hepatitis C. | Academic Article |
Why?
|
| Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C. | Academic Article |
Why?
|
| Sofosbuvir for previously untreated chronic hepatitis C infection. | Academic Article |
Why?
|
| Early identification and linkage to care of persons with chronic hepatitis B virus infection--three U.S. sites, 2012-2014. | Academic Article |
Why?
|
| Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression. | Academic Article |
Why?
|
| The Promise of Direct-Acting Antiviral Therapies to Improve Care and Outcomes in Patients With Cancer Who Have Chronic Hepatitis C Infection. | Academic Article |
Why?
|
| Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. | Academic Article |
Why?
|
| Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir. | Academic Article |
Why?
|
| Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV). | Academic Article |
Why?
|
| Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin. | Academic Article |
Why?
|